Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs

BMC Research Notes

Volumn 6, Issue 1, 2013, Pages

  Umekawa, Kanako ^a   Kimura, Tatsuo ^a   Kudoh, Shinzoh ^a   Suzumura, Tomohiro ^a   Oka, Takako ^a   Nagata, Misato ^a   Mitsuoka, Shigeki ^a   Matsuura, Kuniomi ^a   Nakai, Toshiyuki ^a   Yoshimura, Naruo ^a   Kira, Yukimi ^a   Hirata, Kazuto ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

EGFR TKIs; IL 10; IL 8; NSCLC; RANTES

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; INTERLEUKIN 10; INTERLEUKIN 8; QUINAZOLINE DERIVATIVE; RANTES;

AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION REGULATION; HUMAN; INFLAMMATION; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; TREATMENT OUTCOME; VERY ELDERLY; ARTICLE; DRUG ANTAGONISM; LUNG NON SMALL CELL CANCER; LUNG TUMOR;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOKINE CCL5; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-8; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84875859979     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-6-139     Document Type: Article

References (44)

1. Systemic inflammation, cachexia and prognosis in patients with cancer. Deans C, Wigmore SJ, Curr Opin Clin Nutr Metab Care 2005 8 265 269 10.1097/01.mco.0000165004.93707.88 15809528 (Pubitemid 40586184)
2. Differential regulation of RANTES and IL-8 expression in lung adenocarcinoma cells. Henriquet C, Gougat C, Combes A, Lazennec G, Mathieu M, Lung Cancer 2007 56 167 174 10.1016/j.lungcan.2006.12.003 17207890 (Pubitemid 46590485)
3. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH, Cancer Res 2002 62 5749 5754 12384534 (Pubitemid 35204731)
4. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J, J Clin Oncol 2003 21 2237 2246 10.1200/JCO.2003.10.038 12748244 (Pubitemid 46621858)
5. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC, JAMA 2003 290 2149 2158 10.1001/jama.290.16.2149 14570950 (Pubitemid 37432975)
6. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P, J Clin Oncol 2004 22 3238 3247 10.1200/JCO.2004.11.057 15310767 (Pubitemid 41103678)
7. Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. Luppi F, Longo AM, de Boer WI, Rabe KF, Hiemstra PS, Lung Cancer 2007 56 25 33 10.1016/j.lungcan. 2006.11.014 17175059 (Pubitemid 46356635)
8. Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells. Akca H, Tani M, Hishida T, Matsumoto S, Yokota J, Lung Cancer 2006 54 25 33 10.1016/j.lungcan.2006.06.007 16872715
9. Potential mechanism of interleukin-8 production from lung cancer cells: an involvement of EGF-EGFR-PI3K-Akt-Erk pathway. Zhang Y, Wang L, Zhang M, Jin M, Bai C, Wang X, J Cell Physiol 2012 227 35 43 10.1002/jcp.22722 21412767
10. Periplocin inhibits growth of lung cancer in vitro and in vivo by blocking AKT/ERK signaling pathways. Lu ZJ, Zhou Y, Song Q, Qin Z, Zhang H, Zhou YJ, Gou LT, Yang JL, Luo F, Cell Physiol Biochem 2010 26 609 618 10.1159/000322328 21063098
11. Oncogenic PI3K deregulates transcription and translation. Bader AG, Kang S, Zhao L, Vogt PK, Nat Rev Cancer 2005 5 921 929 10.1038/nrc1753 16341083 (Pubitemid 41766781)
12. PIK3CA mutations and copy number gains in human lung cancers. Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, Soh J, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Date H, Lam WL, Minna JD, Gazdaret AF, Cancer Res 2008 68 6913 6921 10.1158/0008-5472.CAN-07-5084 18757405
13. The immune system evolved to discriminate infectious nonself from noninfectious self. Janeway CA Jr, Immunol Today 1992 13 11 16 10.1016/0167-5699(92)90198-G 1739426
14. Lung adenocarcinoma invasion in TGFbetaRII-deficient cells is mediated by CCL5/RANTES. Borczuk AC, Papanikolaou N, Toonkel RL, Sole M, Gorenstein LA, Ginsburg ME, Sonett JR, Friedman RA, Powell CA, Oncogene 2008 27 557 564 10.1038/sj.onc.1210662 17653092
15. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, Abe A, Clin Cancer Res 2001 7 285 289 11234881 (Pubitemid 32183031)
16. Tgf-beta signaling pathway in lung adenocarcinoma invasion. Toonkel RL, Borczuk AC, Powell CA, J Thorac Oncol 2010 5 153 157 10.1097/JTO. 0b013e3181c8cc0c 20101143
17. RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Moran CJ, Arenberg DA, Huang CC, Giordano TJ, Thomas DG, Misek DE, Chen G, Iannettoni MD, Orringer MB, Hanash S, Beer DG, Clin Cancer Res 2002 8 3803 3812 12473593 (Pubitemid 35424773)
18. Protein kinase C (PKC) family in cancer progression. Koivunen J, Aaltonen V, Peltonen J, Cancer Lett 2006 235 1 10 10.1016/j.canlet.2005.03.033 15907369
19. Protein kinase C: a target for anticancer drugs? Mackay HJ, Twelves CJ, Endocr Relat Cancer 2003 10 389 396 10.1677/erc.0.0100389 14503915 (Pubitemid 37267557)
20. Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional significance of enhanced expression of PKC alpha. Blobe GC, Sachs CW, Khan WA, Fabbro D, Stabel S, Wetsel WC, Obeid LM, Fine RL, Hannun YA, J Biol Chem 1993 268 658 664 8093247 (Pubitemid 23021373)
21. Epidermal growth factor induces phosphorylation of extracellular signal-regulated kinase 2 via multiple pathways. Burgering BM, de Vries-Smits AM, Medema RH, van Weeren PC, Tertoolen LG, Bos JL, Mol Cell Biol 1993 13 7248 7256 8246947 (Pubitemid 23354248)
22. Protein kinase C-{alpha} mediates epidermal growth factor receptor transactivation in human prostate cancer cells. Stewart JR, O'Brian CA, Mol Cancer Ther 2005 4 726 732 10.1158/1535-7163.MCT-05-0013 15897236 (Pubitemid 40767116)
23. Interleukin-10: new perspectives on an old cytokine. Mosser DM, Zhang X, Immunol Rev 2008 226 205 218 10.1111/j.1600-065X.2008.00706.x 19161426
24. Interleukin-10 haplotype may predict survival and relapse in resected non-small cell lung cancer. Wang YC, Sung WW, Wu TC, Wang L, Chien WP, Cheng YW, Chen CY, Shieh SH, Lee H, PLoS One 2012 7 39525 10.1371/journal.pone.0039525 22848356
25. Elevated RANTES levels in plasma or skin and decreased plasma IL-10 levels in subsets of patients with severe atopic dermatitis. Niwa Y, Arch Dermatol 2000 136 125 126 10.1001/archderm.136.1.125 10632223 (Pubitemid 30038836)
26. Persistence of epidermal growth factor receptor and interleukin 10 in blood of colorectal cancer patients after surgery identifies patients with high risk to relapse. Giacomelli L, Gianni W, Belfiore C, Gandini O, Repetto L, Filippini A, Frati L, Agliano AM, Gazzaniga P, Clin Cancer Res 2003 9 2678 2682 12855647 (Pubitemid 36842113)
27. The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients. Masuya D, Huang C, Liu D, Kameyama K, Hayashi E, Yamauchi A, Kobayashi S, Haba R, Yokomise H, Cancer 2001 92 2628 2638 10.1002/1097-0142(20011115)92: 10<2628::AID-CNCR1616>3.0.CO;2-F 11745198 (Pubitemid 33049447)
28. Cytokines and therapy in COPD: a promising combination? De Boer WI, Chest 2002 121 209S 218S 10.1378/chest.121.5-suppl.209S 12010854 (Pubitemid 34497343)
29. Effects of tumor necrosis factor-alpha, epidermal growth factor and transforming growth factor-alpha on interleukin-8 production by, and human rhinovirus replication in, bronchial epithelial cells. Subauste MC, Proud D, Int Immunopharmacol 2001 1 1229 1234 10.1016/S1567-5769(01)00063-7 11460304 (Pubitemid 32522977)
30. Autocrine ligands for the epidermal growth factor receptor mediate interleukin-8 release from bronchial epithelial cells in response to cigarette smoke. Richter A, O'Donnell RA, Powell RM, Sanders MW, Holgate ST, Djukanovic R, Davies DE, Am J Respir Cell Mol Biol 2002 27 85 90 10.1165/ajrcmb.27.1.4789 12091250 (Pubitemid 34657395)
31. Inhibitory effects of andrographolide on migration and invasion in human non-small cell lung cancer A549 cells via down-regulation of PI3K/Akt signaling pathway. Lee YC, Lin HH, Hsu CH, Wang CJ, Chiang TA, Chen JH, Eur J Pharmacol 2010 632 23 32 10.1016/j.ejphar.2010.01.009 20097193
32. Naphtho [1,2-b]furan-4,5-dione inactivates EGFR and PI3K/Akt signaling pathways in human lung adenocarcinoma A549 cells. Su JC, Lin KL, Chien CM, Tseng CH, Chen YL, Chang LS, Lin SR, Life Sci 2010 86 207 213 10.1016/j.lfs.2009.12. 006 20036260
33. Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor. Christensen JG, Vincent PW, Klohs WD, Fry DW, Leopold WR, Elliott WL, Mol Cancer Ther 2005 4 938 947 10.1158/1535-7163.MCT-04-0208 15956251 (Pubitemid 40909076)
34. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, Radinsky R, Dinney CP, Clin Cancer Res 1999 5 257 265 10037173 (Pubitemid 29085177)
35. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Nagai Y, Miyazawa H, Huqun, Tanaka T, Udagawa K, Kato M, Fukuyama S, Yokote A, Kobayashi K, Kanazawa M, Hagiwara K, Cancer Res 2005 65 7276 7282 10.1158/0008-5472.CAN-05-0331 16105816 (Pubitemid 41161259)
36. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweijet J, Eur J Cancer 2009 45 228 247 10.1016/j.ejca.2008.10.026 19097774
37. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P, Semin Radiat Oncol 2003 3 176 81 (Pubitemid 36962641)
38. Role of the insulin-like growth factor family in cancer development and progression. Yu H, Rohan T, J Natl Cancer Inst 2000 92 1472 1489 10.1093/jnci/92.18.1472 10995803
39. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Janne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ, J Clin Oncol 2005 23 5900 5909 10.1200/JCO.2005.02.857 16043828
40. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT, Chen YM, Perng RP, Tsai SF, Tsai CM, Clin Cancer Res 2005 11 3750 3757 10.1158/1078-0432.CCR-04-1981 15897572 (Pubitemid 40685592)
41. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. Lacouture ME, Melosky BL, Skin Therapy Lett 2007 12 1 5 18227953
42. The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome. Lacouture ME, Lai SE, Br J Dermatol 2006 155 852 854 10.1111/j.1365-2133.2006.07452.x 16965448 (Pubitemid 44352579)
43. Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib. Kimura H, Kasahara K, Sekijima M, Tamura T, Nishio K, Lung Cancer 2005 50 393 399 10.1016/j.lungcan.2005.07.012 16153743
44. Reaction of plasma adiponectin level in non-small cell lung cancer patients treated with EGFR-TKIs. Umekawa K, Kimura T, Kudoh S, Suzumura T, Oka T, Nagata M, Mitsuoka S, Matsuura K, Yoshimura N, Kira Y, Hirata K, Osaka City Med J 2012 59 in press